-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 15th, Sino Pharmaceuticals publicly submitted a prospectus to the Hong Kong Stock Exchange for listing on the main board of the Hong Kong Stock Exchange.
//RNA interference mechanism//
RNA interference (RNAi) refers to the highly conserved and specific degradation of homologous mRNA induced by double-stranded RNA in the evolutionary process
//RNAi R&D status//
With the outbreak of the new crown epidemic, RNA therapy has received widespread attention
In addition to vaccines, if RNA therapy can make a major breakthrough in the field of serious diseases such as tumors, then it will become a real highlight of RNA therapy
//Introduction of Shengnuo Pharmaceutical R&D pipeline//
Since its establishment, Sinopharm has established a rich product pipeline, with indications covering cancer, fibrotic diseases, metabolic diseases and viral infections and other diseases
STP705
STP705 is a small interfering RNA (siRNA) therapeutic drug that uses dual-targeted inhibition properties and peptide nanoparticles (PNP) to enhance delivery and directly knock down the expression of TGF-β1 and COX-2
When STP705 was locally injected into human hypertrophic scar tissue transplanted into nude mice, the experimental results showed that the scar size was reduced, and there was fibrosis including α-SMA, hydroxyproline, collagen 1 and collagen 3 Biomarkers are down-regulated
Further analysis found that STP705 can induce fibroblast apoptosis in vitro and in vivo experiments
On July 14, Sanno Pharmaceuticals announced that STP705 has completed the first patient administration in a phase II clinical trial for the prevention of keloids
Other drugs under development include
1.
Designed for systemic administration by using a modified PNP formulation
It is currently being studied for its use in diseases such as liver cancer, multiple solid tumors, liver fibrosis, lung cancer and pulmonary fibrosis
2.
Anticoagulant therapy STP122G
.
Using Sino Pharma’s GalAhead platform and targeted factor XI formulation, targeted factor XI is being developed for anticoagulation therapy for many different medical environments that require antithrombotic therapy
.
It is planned to submit an IND to the FDA in the first half of 2022
.
3.
Preventive mRNA vaccine RIM730
.
A preventive vaccine that is being developed as a preventive vaccine against the new coronavirus is administered by intramuscular injection using the PLNP delivery platform of Sino Pharmaceuticals
.
In addition, Sinopharm also has pipelines for research and development of influenza, hepatitis B, cardiometabolic diseases, pancreatic cancer, colon cancer and other cancers
.
//Establish multiple innovative delivery platforms to overcome the stuck neck problem//
The ability of Sino Pharmaceuticals to achieve coverage in multiple therapeutic areas lies in the company's technological innovation and its core grasp of RNAi technology
.
RNAi drugs are easily degraded and difficult to be endocytosed by target cells.
Therefore, delivery technology has become a major bottleneck in the development of the industry
.
At present, GalNac (three-antennary N-acetylgalactosamine) technology and lipid nanoparticle (LNP) introduction technology are the mainstream delivery technologies in the RNAi field.
However, due to complex production processes and biological barriers, the application of RNAi drugs is limited
.
On this basis, Shengnuo Pharmaceutical has successively built platforms such as peptide nano (PNP) technology, small peptide galactosamine coupling (PDoV-GalNAc) technology, and small nucleic acid chemical drug coupling (siRNA-chemo-conjugate) technology
.
In particular, PNP introduction technology is superior to LNP and GalNac in terms of targeting and efficiency into cells.
Therefore, it is expected that RNAi drugs will be promoted to the fields of tumor treatment, fibrosis treatment and antiviral treatment
.
From the perspective of market development potential, with the continuous technological breakthroughs in recent years, the continuous expansion of the scope of clinical goals, the successful verification of multiple clinical trials, and the increasing investment and cooperation, the global market for RNAi therapy is growing day by day
.
The current global market for RNAi therapy has increased from US$12 million in 2018 to US$362 million in 2020, with a compound annual growth rate of 449.
2%, and is estimated to reach US$21 billion in 2030
.
By 2030, the market size of RNAi therapy for common diseases and oncology will account for 49% of the total market size
.
The development of small nucleic acid drugs has been constrained by the introduction system for many years
.
Nucleic acid interference drugs must enter the cell to start RNAi, and the introduction of the system becomes the key
.
The multiple innovative and proprietary delivery platforms established by Sino Pharmaceuticals have improved the efficiency of drug introduction in the body and strengthened the efficacy of small nucleic acid drugs
.
Sino Bio has become a leader in the development and creation of domestic RNAi drugs, and has become a new force in the field of international nucleic acid drug creation and creation
.
